Screener
Royalty Pharma RPRX EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's EBIT?
- Royalty Pharma (RPRX) reported EBIT of $133.12M in Q2 2026.
- How has Royalty Pharma's EBIT changed year-over-year?
- Royalty Pharma's EBIT decreased by 36.5% year-over-year, from $209.8M to $133.12M.
- What is the long-term trend for Royalty Pharma's EBIT?
- Over 3 years (2021 to 2025), Royalty Pharma's EBIT has grown at a 2.9% compound annual growth rate (CAGR), from $1.43B to $1.56B.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Royalty Pharma's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude